Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech's Lucentis BLA Will Not Include Data Supporting Dosing Advantage

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA denies fast-track designation for the wet age-related macular degeneration product; the company plans to keep the filing on track and submit the more flexible dosing data from its PIER trial in an sBLA.

You may also be interested in...



Genentech's Lucentis Heads to FDA

Genentech is touting the breadth and quality of data for the macular degeneration agent, including two Phase III trials and results showing superiority to Novartis/QLT's Visudyne.

Genentech's Lucentis Heads to FDA

Genentech is touting the breadth and quality of data for the macular degeneration agent, including two Phase III trials and results showing superiority to Novartis/QLT's Visudyne.

Pfizer/Eyetech Sets Sights On Diabetic Macular Edema For Macugen Sales Growth

Eyetech and Pfizer will initiate a Phase II/III pivotal trial during the second half of the year, Eyetech said. The age-related macular degeneration market, for which Macugen is currently approved, may face increasing competition

Related Content

Topics

UsernamePublicRestriction

Register

PS062994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel